MONROE, Ohio, April 16, 2024 /PRNewswire/ -- CSafe, an active
and passive temperature-controlled shipping solutions provider for
the biopharmaceutical industry, proudly announces the launch of a
new line of cryogenic multi-use dewars for the cell and gene
therapy market. The progressive technology, which is the first in
CSafe's CGT Cryo Series, maintains temperatures colder than
-150°C.
The reusable dewars and high-impact-resistant shipping cases are
engineered to securely transport critical cell and gene therapies,
including pre-frozen biologic materials, regenerative medicine,
immunotherapies, stem cells and CAR-T cells.
"The cell and gene therapy industry needs more solutions that
integrate data with products, alongside a global network with
advanced capabilities and service infrastructure," said
Patrick Schafer, CSafe CEO. "Our
team has worked tirelessly to develop these new solutions to ensure
the integrity of our customers' valuable cargo, and ultimately
provide peace of mind."
These cutting-edge solutions offer a myriad of key features
tailored to meet stringent industry standards. Pre-conditioned
using liquid nitrogen, these dry vapor units boast an impressive
hold time of 10+ days against the ISTA 7D thermal profile,
providing high levels of reliability for critical shipments. They
include built-in TracSafe RLT real-time data tracking devices to
monitor internal product temperature, external ambient temperature,
shock, tilt, and location throughout the shipment journey. Through
CSafe Connect, the company's digital portal, customers can easily
track their order, access real-time data, and upgrade to the
premium Control Tower shipment monitoring service for added
monitoring and control.
Additionally, the multi-use dewars deliver extra protection with
security seals and a lockable shipping case to prevent tampering
during transit. The dry vapor unit complies with IATA Dangerous
Goods Regulation, and the shipping case's domed cap prevents
stacking to ensure a stable, upright orientation during transit and
handling. Qualified to industry standards, including ISTA 3A for
distribution and ISTA 7D for thermal qualification, these
high-performance solutions offer peace of mind for customers.
"Our new line of dewars isn't just a product—it's a promise,"
said Emilio Frattaruolo, Vice
President, Cell & Gene Therapies. "A promise of precision and
reliability as we venture into the next frontier of innovation in
cell and gene therapies."
CSafe's multi-use dewars are currently available worldwide, in
two sizes: 4-liter and 10-liter capacity.
Media Contact:
Emma
Lupp
Vice President of Global Marketing
Direct: (41) 44-797-61-25
Email: elupp@csafeglobal.com
Web: csafeglobal.com
About CSafe
CSafe offers a comprehensive suite of
thermal shipping solutions for pharmaceutical cold chain shipping
needs around the world. With a "patient-first" focus, deep industry
expertise and a commitment to innovation, CSafe delivers products
in both the active and passive segments. CSafe's end-to-end
portfolio includes active and passive bulk air cargo, parcel, cell
and gene, and specialty last-mile use cases, meeting a range of
pharma cold-chain shipping requirements with quality and
reliability. Offering nearly any size, duration and
temperature—CSafe is at the heart of your cold chain.
csafeglobal.com
Photo -
https://mma.prnewswire.com/media/2388446/RJW_150324_0526_CSafe.jpg
Logo
- https://mma.prnewswire.com/media/1917781/CSafe_Logo_New.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/csafe-elevates-cell-and-gene-therapy-transport-with-reusable-cryogenic-solution-302118125.html